A Phase 2 interventional study of Miricorilant and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by Corcept Therapeutics. Terminated at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-31.
Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 402nd largest by enrollment of the 460 interventional ones that give a count, is one of 39 that started in 2020, is one of 192 in phase 2, and was the 272nd registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 39 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
Corcept Therapeutics has 8 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
This is a randomized, double-blind, placebo-controlled study that assessed the safety efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). Patients who meet the criteria for Study CORT118335-860 were randomized on Day 1 to receive 900 mg miricorilant, 600 mg miricorilant, or placebo for 12 weeks.
Due to observations related to safety, the study was terminated prior to completion and study objectives, endpoints, and procedures were modified as specified in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 900 mg miricorilant (6 miricorilant tablets of 150 mg) orally once daily.
Drug: Miricorilant
Participants received 600 mg miricorilant (4 miricorilant tablets of 150 mg and 2 placebo tablets) orally once daily.
Drug: Miricorilant · Drug: Placebo
Participants received 6 placebo tablets orally once daily.
Drug: Placebo
Tablets taken orally
Also known as: CORT118335
Placebo tablets
Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction
The change from baseline in liver fat content (LFC) by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for each miricorilant dose level (600 mg, 900 mg) versus placebo was assessed. MRI-PDFF was performed to determine the degree of LFC reduction. The relative change is defined for each participant as %: (\[Post-Baseline LFC-Baseline LFC\]/Baseline LFC) × 100. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and up to ~Day 95
Number of Participants Achieving a Relative Reduction From Baseline in LFC of ≥30% by MRI-PDFF
The number of participants (defined as responders) with a ≥30% reduction in LFC from baseline by treatment group as assessed by MRI-PDFF. The number of participants with a reduction in LFC from baseline of \<30% were defined as non-responders. MRI-PDFF was performed at screening and up to 33 days after last dose of study drug. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and up to ~Day 95
Change From Baseline in Aspartate Aminotransferase
The change in aspartate aminotransferase (AST) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and Week 6
Change From Baseline in Alanine Aminotransferase
The change in serum alanine aminotransferase (ALT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and Week 6
Change From Baseline in Gamma-glutamyl Transferase
The change in gamma-glutamyl transferase (GGT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and Week 6
Change From Baseline in Propeptide of Type III Collagen
The change in serum propeptide of Type III collagen (pro-C3) from baseline at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and Week 6
Change From Baseline in Enhanced Liver Fibrosis Score
The change in enhanced liver fibrosis (ELF) from baseline for each treatment group at the Week 6 visit is summarized. The ELF score combines 3 serum biomarkers (hyaluronic acid, tissue inhibitor of metalloproteinases-1 \[TIMP-1\] and type III procollagen \[PIIINP\]) which have been shown to correlate with the degree of liver fibrosis assessed by liver biopsy. Each of these markers is measured by an immunoassay and an ELF score is generated \[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)\], from which a level of fibrosis severity can be determined; higher ELF scores are associated with worsening liver fibrosis. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
Time frame: Baseline and Week 6
Number of Participants With a Relative Reduction in Liver Fat Content ≥50% by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) for Miricorilant Versus Placebo
Time frame: Baseline and up to ~Day 95
Number of Participants With Complete Resolution in Liver Fat by MRI-PDFF for Miricorilant Versus Placebo
Time frame: Baseline and up to ~Day 95
| Milestone | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Started | 3 | 5 | 4 |
| Treated | 3 | 5 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 5 | 4 |
| Withdrew: Sponsor request | 0 | 3 | 4 |
| Withdrew: Adverse event | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The change from baseline in liver fat content (LFC) by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for each miricorilant dose level (600 mg, 900 mg) versus placebo was assessed. MRI-PDFF was performed to determine the degree of LFC reduction. The relative change is defined for each participant as %: (\[Post-Baseline LFC-Baseline LFC\]/Baseline LFC) × 100. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| Percent change | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction | -50.28 ± 13.723 | -22.94 ± 71.943 | 4.63 ± 5.232 |
The number of participants (defined as responders) with a ≥30% reduction in LFC from baseline by treatment group as assessed by MRI-PDFF. The number of participants with a reduction in LFC from baseline of \<30% were defined as non-responders. MRI-PDFF was performed at screening and up to 33 days after last dose of study drug. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| Participants | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Responders with a reduction in LFC from baseline of ≥30% | 3 | 1 | 0 |
| Non-responders with a reduction in LFC from baseline of <30% | 0 | 1 | 2 |
The change in aspartate aminotransferase (AST) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| units per liter (U/L) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Aminotransferase | 346.0 ± NA | 321.0 ± NA | -9.5 ± 3.54 |
The change in serum alanine aminotransferase (ALT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| U/L | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Aminotransferase | 810.0 ± NA | 826.0 ± NA | -16 ± 2.83 |
The change in gamma-glutamyl transferase (GGT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| U/L | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-glutamyl Transferase | 29.0 ± NA | 82.0 ± NA | -26.0 ± 31.11 |
The change in serum propeptide of Type III collagen (pro-C3) from baseline at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| μg/L | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Propeptide of Type III Collagen | 4.0 ± NA | — | -1.65 ± 2.475 |
The change in enhanced liver fibrosis (ELF) from baseline for each treatment group at the Week 6 visit is summarized. The ELF score combines 3 serum biomarkers (hyaluronic acid, tissue inhibitor of metalloproteinases-1 \[TIMP-1\] and type III procollagen \[PIIINP\]) which have been shown to correlate with the degree of liver fibrosis assessed by liver biopsy. Each of these markers is measured by an immunoassay and an ELF score is generated \[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)\], from which a level of fibrosis severity can be determined; higher ELF scores are associated with worsening liver fibrosis. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.
| ELF score | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Enhanced Liver Fibrosis Score | 1.050 ± NA | — | 0.225 ± 0.459 |
| Participants | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Responders | 1 | 1 | 0 |
| Non-Responders | 2 | 1 | 2 |
| Participants | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Responders | 0 | 1 | 0 |
| Non-Responders | 3 | 1 | 2 |
Collected over Up to ~Day 95 for all cause mortality, serious adverse events and other non-serious treatment-emergent adverse events (TEAEs) during the study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Miricorilant- 900 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Miricorilant- 600 mg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 2/3 | 0/5 | 0/4 |
| Alanine aminotransferase increasedInvestigations | 1/3 | 0/5 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/5 | 0/4 |
| Event | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo |
|---|---|---|---|
| Influenza like illnessGeneral disorders | 2/3 | 0/5 | 0/4 |
| Alanine aminotransferase increasedInvestigations | 2/3 | 1/5 | 0/4 |
| HeadacheNervous system disorders | 1/3 | 2/5 | 0/4 |
| EosinophiliaBlood and lymphatic system disorders | 1/3 | 0/5 | 0/4 |
| VertigoEar and labyrinth disorders | 1/3 | 0/5 | 0/4 |
| Abdominal distensionGastrointestinal disorders | 1/3 | 1/5 | 0/4 |
| ConstipationGastrointestinal disorders | 1/3 | 0/5 | 0/4 |
| NauseaGastrointestinal disorders | 1/3 | 0/5 | 0/4 |
| VomitingGastrointestinal disorders | 1/3 | 0/5 | 0/4 |
| MalaiseGeneral disorders | 1/3 | 0/5 | 0/4 |
| Age, Continuous(years) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 55.7 ± 14.74 | 54.2 ± 19.87 | 43.3 ± 15.15 | 50.9 ± 16.68 |
| Sex: Female, Male(Participants) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 2 | 6 |
| Male | 1 | 3 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 0 | 4 |
| Not Hispanic or Latino | 1 | 3 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 5 | 3 | 11 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 3 | 5 | 4 | 12 |
| Liver Fat Content (LFC) Assessed by MRI-PDFF(Percentage of liver fat content) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 24.57 ± 6.038 | 15.70 ± 6.536 | 19.93 ± 8.750 | 19.33 ± 7.526 |
| Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) & Gamma Glutamyl Transferase (GGT)(Units/Liter (U/L)) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| AST | 35.7 ± 8.14 | 25.6 ± 12.76 | 31 ± 4.08 | 29.9 ± 9.68 |
| ALT | 52.3 ± 15.63 | 33.2 ± 15.94 | 54.0 ± 12.11 | 44.9 ± 16.86 |
| GGT | 52.7 ± 19.63 | 26.2 ± 9.20 | 59.0 ± 50.29 | 43.8 ± 32.20 |
| Propeptide of Type III Collagen (Pro-C3)(micrograms/liter (μg/L)) | Miricorilant- 900 mg | Miricorilant- 600 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 16.13 ± 5.350 | 11.20 ± 2.189 | 13.73 ± 4.727 | 13.28 ± 4.159 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Apr 2021, 5 months.
Results were first posted in Aug 2022, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CORT118335
Non-alcoholic Fatty Liver Disease →